Opus Genetics, Inc. Retained Earnings
Opus Genetics, Inc. (IRD) had Retained Earnings of -$262.22 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$262.22M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$254.12M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$188.59M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$172.07M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$262.22M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | -$254.12M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | -$188.59M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | -$172.07M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | -$154.61M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | -$147.19M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | -$139.00M 10-K · filed 2026-03-12 | |
| 2024-09-30 | -$103.86M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | -$96.34M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | -$88.57M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | -$81.47M 10-K · filed 2025-03-31 | |
| 2023-09-30 | -$76.67M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | -$82.23M 10-Q · filed 2023-08-11 | |
| 2023-03-31 | -$77.27M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | -$71.48M 10-K · filed 2024-03-08 | |
| 2022-09-30 | -$105.42M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | -$100.89M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | -$95.96M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | -$89.37M 10-K · filed 2023-03-30 | |
| 2021-09-30 | -$83.06M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | -$78.83M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | -$71.69M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | -$32.67M 10-K · filed 2022-03-24 | |
| 2020-09-30 | -$167.82M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | -$166.42M 10-Q · filed 2020-08-14 | |
| 2020-03-31 | -$163.91M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | -$8.05M 10-K · filed 2021-03-11 | -$163.32M 10-K · filed 2020-02-21 |
| 2019-09-30 | -$161.45M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | -$159.49M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | -$157.03M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | -$154.69M 10-K · filed 2020-02-21 | |
| 2018-09-30 | -$151.57M 10-Q · filed 2018-11-02 | |
| 2018-06-30 | -$146.23M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | -$142.39M 10-Q · filed 2018-05-04 | |
| 2017-12-31 | -$140.32M 10-K · filed 2019-03-07 | |
| 2017-09-30 | -$136.73M 10-Q · filed 2017-11-03 | |
| 2017-06-30 | -$135.69M 10-Q · filed 2017-08-04 | |
| 2017-03-31 | -$136.64M 10-Q · filed 2017-05-03 | |
| 2016-12-31 | -$115.02M 10-K · filed 2018-03-09 | |
| 2016-09-30 | -$114.50M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | -$111.63M 10-Q · filed 2016-08-05 | |
| 2016-03-31 | -$109.87M 10-Q · filed 2016-05-06 | |
| 2015-12-31 | -$105.72M 10-K · filed 2017-02-24 | |
| 2015-09-30 | -$102.86M 10-Q · filed 2015-11-02 | |
| 2015-06-30 | -$98.84M 10-Q · filed 2015-08-07 | |
| 2015-03-31 | -$95.60M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | -$91.33M 10-K · filed 2016-03-14 | |
| 2014-09-30 | -$89.12M 10-Q · filed 2014-11-12 | |
| 2014-06-30 | -$87.22M 10-Q · filed 2014-08-13 | |
| 2013-12-31 | -$72.81M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |